NSCLC Survival Benefit Seen With EGFR-TKI + Chemo

Median PFS benefit was just over 3 months in patients with EGFR-mutant NSCLC who had tumor suppressor gene co-mutations. Medscape Medical News

Read the full article on medscape.com